Truist Financial Corp lowered its position in Exponent, Inc. (NASDAQ:EXPO - Free Report) by 8.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 71,636 shares of the business services provider's stock after selling 6,333 shares during the quarter. Truist Financial Corp owned about 0.14% of Exponent worth $6,383,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently made changes to their positions in EXPO. Creative Planning increased its stake in Exponent by 24.9% in the 3rd quarter. Creative Planning now owns 21,320 shares of the business services provider's stock worth $2,458,000 after acquiring an additional 4,250 shares during the last quarter. International Assets Investment Management LLC purchased a new position in shares of Exponent during the third quarter worth about $11,261,000. Arkadios Wealth Advisors increased its position in shares of Exponent by 40.3% in the third quarter. Arkadios Wealth Advisors now owns 23,207 shares of the business services provider's stock worth $2,675,000 after purchasing an additional 6,665 shares during the last quarter. Wealth Enhancement Advisory Services LLC bought a new position in shares of Exponent in the third quarter worth approximately $215,000. Finally, State of Alaska Department of Revenue raised its stake in Exponent by 7.2% in the third quarter. State of Alaska Department of Revenue now owns 5,866 shares of the business services provider's stock valued at $676,000 after purchasing an additional 395 shares in the last quarter. Hedge funds and other institutional investors own 92.37% of the company's stock.
Exponent Price Performance
EXPO stock traded up $0.26 during midday trading on Monday, reaching $84.78. The company had a trading volume of 452,790 shares, compared to its average volume of 238,620. The firm has a 50-day moving average price of $90.26 and a 200-day moving average price of $99.40. The company has a market capitalization of $4.30 billion, a P/E ratio of 39.99 and a beta of 0.71. Exponent, Inc. has a 1 year low of $77.21 and a 1 year high of $115.75.
Exponent (NASDAQ:EXPO - Get Free Report) last posted its quarterly earnings data on Thursday, February 6th. The business services provider reported $0.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.40 by $0.06. Exponent had a net margin of 19.52% and a return on equity of 27.27%. During the same quarter in the prior year, the company posted $0.41 earnings per share. On average, equities analysts predict that Exponent, Inc. will post 1.98 EPS for the current year.
Exponent Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 21st. Stockholders of record on Friday, March 7th will be given a dividend of $0.30 per share. The ex-dividend date of this dividend is Friday, March 7th. This is a positive change from Exponent's previous quarterly dividend of $0.28. This represents a $1.20 annualized dividend and a dividend yield of 1.42%. Exponent's dividend payout ratio is 52.83%.
Exponent Company Profile
(
Free Report)
Exponent, Inc, together with its subsidiaries, operates as a science and engineering consulting company in the United States and internationally. The company operates in two segments, Engineering and Other Scientific, and Environmental and Health. The Engineering and Other Scientific segment provides services in the areas of biomechanics, biomedical engineering and sciences, buildings and structures, civil engineering, construction consulting, data sciences, electrical engineering and computer science, human factors, materials and corrosion engineering, mechanical engineering, polymer science and materials chemistry, thermal sciences, and vehicle engineering.
Read More

Before you consider Exponent, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Exponent wasn't on the list.
While Exponent currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.